Marex Group’s Compass Therapeutics CMPX Stock Holding History

Marex Group’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,600	Closed	-$61.4K	–	882
2025 Q2	$61.4K	Hold	23,600	–	–	﹤0.01%	589
2025 Q1	$44.8K	Buy	+23,600	New	+$62.8K	﹤0.01%	644

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Marex Group's CMPX Position: Q3 2025 in Review

Marex Group sold out of Compass Therapeutics (CMPX) in Q3 2025, closing a stake of 23,600 shares — an estimated $61.4K sold.

Marex Group first reported a position in CMPX in Q1 2025 and held it in 2 quarters. The position peaked at $61.4K in Q2 2025. 125 funds tracked by Wall St. Rank hold CMPX as of Q3 2025.

Marex Group reported no remaining Compass Therapeutics position as of Q3 2025 after selling out during the quarter.
Marex Group sold 23,600 Compass Therapeutics shares in Q3 2025, an estimated $61.4K.
Marex Group first reported a position in Compass Therapeutics in Q1 2025 and held it in 2 quarters.
Marex Group's Compass Therapeutics position peaked at $61.4K in Q2 2025.
125 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.